Belgian biotech firm Ablynx recently announced that it has entered into a second agreement with Merck Serono to co-develop Nanobodies against an undisclosed inflammatory disease target. Under the terms of the agreement, Ablynx...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)